tiprankstipranks
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
PremiumPress ReleasesApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
1M ago
Applied Therapeutics: FDA extends review period for NDA for govorestat
PremiumThe Fly
Applied Therapeutics: FDA extends review period for NDA for govorestat
1M ago
Applied Therapeutics initiated with an Outperform at RBC Capital
PremiumThe Fly
Applied Therapeutics initiated with an Outperform at RBC Capital
1M ago
Applied Therapeutics price target raised to $12 from $4 at UBS
PremiumThe FlyApplied Therapeutics price target raised to $12 from $4 at UBS
2M ago
Applied Therapeutics reports FY23 EPS ($1.42), consensus ($1.42)
PremiumThe Fly
Applied Therapeutics reports FY23 EPS ($1.42), consensus ($1.42)
2M ago
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
PremiumPress Releases
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
2M ago
Applied Therapeutics initiated with an Outperform at Leerink
PremiumThe FlyApplied Therapeutics initiated with an Outperform at Leerink
2M ago
Applied Therapeutics price target raised to $7 from $5 at Citi
PremiumThe Fly
Applied Therapeutics price target raised to $7 from $5 at Citi
3M ago
Applied Therapeutics’ Govorestat Shows Promise in Phase 3 Trial
PremiumCompany Announcements
Applied Therapeutics’ Govorestat Shows Promise in Phase 3 Trial
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100